Albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine benefits patients with metastatic pancreatic cancer, according to the findings of a phase III study published in New England Journal of Medicine. Combined therapy significantly improved progression-free survival, overall survival and response rate compared with gemcitabine monotherapy. Grade 3 adverse events more frequent in the combined therapy group included neutropenia, fatigue and neuropathy.